等待开盘
0.000
NaN.00%
Ruling preserves current contracted royalty rates and rejects Tesaro's request for any royalty reductionTrial to adjudicate Anaptys' contract claims and right to seek reversion of Jemperli against Tesaro/GSK is scheduled
04-25 03:43
之前关注的多是ADC、双抗等BD出海预期强的管线/公司,非肿管线看的不多。目前肿瘤赛道愈发拥挤,国内非肿创新项目占比明显升高,意味着我也必须将能力圈拓展至非肿管...
04-09 13:35
AnaptysBio asks a Delaware court to dismiss Tesaro's breach claim, citing anti-SLAPP law in a dispute over Jemperli royalties and licensing rights.
01-10 02:56
GSK's Tesaro sues AnaptysBio over alleged Jemperli contract breaches, putting royalties, milestones, and future licensing rights into question.
2025-11-21 21:48